Advertisement
Plegridy, a new interferon product, has received U.S. Food and Drug Administration (FDA) approval as a treatment for relapsing forms of multiple sclerosis (MS). In a clinical trial, Plegridy was shown to significantly reduce important clinical and imaging measures, including slowing the progression of disability and decreasing the number of relapses and brain lesions. Plegridy is given by subcutaneous injection every two weeks.
Continue Learning about Multiple Sclerosis Treatment
Important: This content reflects information from various individuals and organizations and may offer alternative or opposing points of view. It should not be used for medical advice, diagnosis or treatment. As always, you should consult with your healthcare provider about your specific health needs.